Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + pomalidomide + dexamethasone for multiple myeloma with central nervous system involvement
ChiCTR2200056014Phase 4Recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- Jan 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of selinexor, pomalidomide and dexamethasone in multiple myeloma (MM), sponsored by Qingdao Municipal Hospital. Primary endpoint: Progression-free survival. Started Jan 2022; status: recruiting.
02
Drugs
selinexorpomalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2200056014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056014.